Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
FHTX compared with GENB: revenue, margins and what each company keeps, and the suppliers and customers both name
FHTX
Foghorn Therapeutics Inc.
Change
Mkt cap
Revenue
Revenue
GENB
Generate Biomedicines, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
FHTX
Foghorn Therapeutics Inc.
vs
GENB
Generate Biomedicines, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
FHTX: latest quarter is a loss; flow not drawable. GENB: latest quarter is a loss; flow not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
FHTX, solid
GENB, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only FHTX
2
LLY
Eli Lilly
customer
MRK
Merck Sharp & Dohme
customer
Shared
0
No shared counterparties.
Only GENB
4
AMGN
Amgen
customer
NVS
Novartis Pharma
customer
—
The University of Texas MD Anderson Cancer Center
unlisted
supplier
—
Roswell Park Comprehensive Cancer Center
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
unlisted
supplier
FHTX
Foghorn Therapeutics Inc.
Change
2.08
▼
−0.48%
· post 2.08
Mkt cap
$123.5M
Revenue
$16M
Q2 FY26
Revenue
$31M
FY25
GENB
Generate Biomedicines, Inc.
Change
14.49
▼
−8.10%
· post 14.49
Closed
Oct 30 '26
Mkt cap
$1.9B
Revenue
$6M
Q2 FY26
Revenue
—
vs
Compare
Closed
Oct 30 '26
FHTX
Foghorn Therapeutics Inc.
vs
GENB
Generate Biomedicines, Inc.
2.08
▼
−0.48%
post 2.08
Price
14.49
▼
−8.10%
post 14.49
$123.5M
Mkt cap
$1.9B
Q2 FY26
$16M
Revenue
$6M
Q2 FY26
FY25
$31M
Revenue
—
Change
Change
FHTX
2.08
▼
−0.48%
vs
GENB
14.49
▼
−8.10%
Closed
Oct 30 '26